Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 19.02.2024 1 ACS Nano 3 Aktuelle Urol 2 Ann Oncol 2 Arch Ital Urol Androl 3 Asia Pac J Clin Oncol 1 Asian J Endosc Surg 1 Biochem Genet 2 BMC Cancer 1 BMC Urol 1 BMJ 1 Cancer Med 1 Cancer Sci 1 Cancers (Basel) 1 Chem Biol Drug Des 1 Chembiochem 4 Clin Genitourin Cancer 1 Clin Radiol 1 Clin Transl Oncol 1 Curr Med Chem 1 Eur J Med Res 4 Eur Urol 1 Expert Rev Anticancer Ther 1 Folia Med (Plovdiv) 1 Gene 1 Heliyon 2 Indian J Pathol Microbiol 1 Int J Hyperthermia 3 Int J Mol Sci 1 Int J Surg 3 Int Urol Nephrol 1 Integr Cancer Ther 1 J Clin Med 1 J Coll Physicians Surg Pak 1 J Urol 2 JAMA Oncol 1 Lakartidningen 2 Med 1 Mol Cancer 1 Mol Oncol 2 Nat Commun 1 Neuropathol Appl Neurobiol 1 Pathol Res Pract 1 Pharm Biol 1 Radiat Oncol 1 Sci Rep 1 Transl Res 4 Urol Oncol 1 Urologie 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Nano

1. WEI Y, Zhao M, He T, Chen N, et al
   Quantitatively Lighting up the Spatial Organization of CD47/SIRPalpha Immune Checkpoints on the Cellular Membrane with Single-Molecule Localization Microscopy.
   ACS Nano. 2023;17:21626-21638.
   PubMed         Abstract available
   
   

   
   Aktuelle Urol

2. 
   [Not Available].
   Aktuelle Urol. 2024;55:18-20.
   PubMed        
   
   
3. 
   [Not Available].
   Aktuelle Urol. 2024;55:22-23.
   PubMed        
   
   
4. 
   [Not Available].
   Aktuelle Urol. 2024;55:24-25.
   PubMed        
   
   

   
   Ann Oncol

5. NECCHI A, Pouessel D, Leibowitz R, Gupta S, et al
   Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
   Ann Oncol. 2024;35:200-210.
   PubMed         Abstract available
   
   
6. SONPAVDE GP, Subbiah V
   Unlocking precision oncology with FGFR inhibition in urothelial carcinoma.
   Ann Oncol. 2024;35:150-153.
   PubMed        
   
   

   
   Arch Ital Urol Androl

7. RAHMAN ZA, Hidayatullah F, Lim J, Hakim L, et al
   A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
   Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12154.
   PubMed         Abstract available
   
   
8. PRONTERA PP, Prusciano FR, Lattarulo M, Utano E, et al
   Quality of bladder cancer treatment information on YouTube: May the user's profile affect the quality of results?
   Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12179.
   PubMed         Abstract available
   
   

   
   Asia Pac J Clin Oncol

9. TAN KL, Viswambaram P, McCombie S, Moe A, et al
   Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette-Guerin.
   Asia Pac J Clin Oncol. 2023;19:697-705.
   PubMed         Abstract available
   
   
10. PARK K, Lee HJ, Kim TU, Ryu H, et al
    Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
    Asia Pac J Clin Oncol. 2023;19:739-746.
    PubMed         Abstract available
    
    
11. GURNEY H, Clay TD, Oliveira N, Wong S, et al
    Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia.
    Asia Pac J Clin Oncol. 2023;19:585-595.
    PubMed         Abstract available
    
    

    
    Asian J Endosc Surg

12. SUZUKI A, Ito H, Uemura K, Muraoka K, et al
    Surgical proficiency in laparoscopic radical cystectomy with extracorporeal urinary diversion and its adequacy for the execution of robot-assisted radical cystectomy with intracorporeal urinary diversion.
    Asian J Endosc Surg. 2024;17:e13289.
    PubMed         Abstract available
    
    

    
    Biochem Genet

13. LI C, Qin W, Hu J, Lin J, et al
    A Machine Learning Computational Framework Develops a Multiple Programmed Cell Death Index for Improving Clinical Outcomes in Bladder Cancer.
    Biochem Genet. 2024 Feb 14. doi: 10.1007/s10528-024-10683.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    PubMed         Abstract available
    
    
15. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    PubMed         Abstract available
    
    

    
    BMC Urol

16. IBRAHIM M, Rabinowitz J, Hilbert R, Ghose A, et al
    The role of URO17(R) in diagnosis and follow up of bladder cancer patients.
    BMC Urol. 2024;24:34.
    PubMed         Abstract available
    
    

    
    BMJ

17. LOPEZ-BELTRAN A, Cookson MS, Guercio BJ, Cheng L, et al
    Advances in diagnosis and treatment of bladder cancer.
    BMJ. 2024;384:e076743.
    PubMed         Abstract available
    
    

    
    Cancer Med

18. HUANG SY, Su PJ, Lin CT, Kuo MC, et al
    The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis.
    Cancer Med. 2024;13:e7008.
    PubMed         Abstract available
    
    

    
    Cancer Sci

19. TAMURA D, Abe M, Hiraki H, Sasaki N, et al
    Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
    Cancer Sci. 2024;115:529-539.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

20. LU Q, Wang J, Tao Y, Zhong J, et al
    Small Cajal Body-Specific RNA12 Promotes Carcinogenesis through Modulating Extracellular Matrix Signaling in Bladder Cancer.
    Cancers (Basel). 2024;16:483.
    PubMed         Abstract available
    
    

    
    Chem Biol Drug Des

21. SU Y, Chen L, Yang J
    Network pharmacology and in vitro experiments reveal sophoridine-induced apoptosis and G(1) phase arrest via ROS-dependent PI3K/Akt/FoxO3a pathway activation in human bladder cancer cells.
    Chem Biol Drug Des. 2024;103:e14476.
    PubMed         Abstract available
    
    

    
    Chembiochem

22. BRETON-PATIENT C, Billotte S, Duchambon P, Fontaine G, et al
    Light-Activatable Photocaged UNC2025 for Triggering TAM Kinase Inhibition in Bladder Cancer.
    Chembiochem. 2024 Feb 16:e202300855. doi: 10.1002/cbic.202300855.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

23. CARMONA O, Kleinmann N, Zilberman DE, Dotan ZA, et al
    Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of Upper Tract Urothelial Carcinoma?
    Clin Genitourin Cancer. 2024;22:98-105.
    PubMed         Abstract available
    
    
24. KAWADA T, Yanagisawa T, Rajwa P, Motlagh RS, et al
    The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2024 Jan 17:S1558-7673(24)00009.
    PubMed         Abstract available
    
    
25. JOYCE DD, Shan Y, Stewart CA, Chamie K, et al
    A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:14-22.
    PubMed         Abstract available
    
    
26. MATHAVAN A, Mathavan A, Murillo-Alvarez R, Gera K, et al
    Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies.
    Clin Genitourin Cancer. 2024;22:67-75.
    PubMed        
    
    

    
    Clin Radiol

27. CAO B, Li Q, Xu P, Zhang Y, et al
    Vesical Imaging-Reporting and Data System (VI-RADS) as a grouping imaging biomarker combined with a decision-tree mode to preoperatively predict the pathological grade of bladder cancer.
    Clin Radiol. 2024 Feb 9:S0009-9260(24)00082-5. doi: 10.1016/j.crad.2024.
    PubMed         Abstract available
    
    

    
    Clin Transl Oncol

28. SOTELO M, Munoz-Unceta N, Matorras A, Jara P, et al
    Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution.
    Clin Transl Oncol. 2024;26:682-688.
    PubMed         Abstract available
    
    

    
    Curr Med Chem

29. SU Y, Chen L, Yang J
    Hesperetin Inhibits Bladder Cancer Cell Proliferation and Promotes Apoptosis and Cycle Arrest by PI3K/AKT/FoxO3a and ER Stress-mitochondria Pathways.
    Curr Med Chem. 2024 Feb 13. doi: 10.2174/0109298673283888231217174702.
    PubMed         Abstract available
    
    

    
    Eur J Med Res

30. TANG R, Wang H, Liu J, Song L, et al
    TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Eur J Med Res. 2024;29:112.
    PubMed         Abstract available
    
    

    
    Eur Urol

31. SHARIAT SF, Laukhtina E
    Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34.
    Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
32. FENG YN, Xie GY, Xiao L
    Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
    Eur Urol. 2023;84:e145.
    PubMed        
    
    
33. PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
    Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Blad
    Eur Urol. 2023;84:e154.
    PubMed        
    
    
34. LI DX, Feng DC, Deng S
    Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-gui
    Eur Urol. 2023;84:e152-e153.
    PubMed        
    
    

    
    Expert Rev Anticancer Ther

35. FILIPPI L, Schillaci O
    NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
    Expert Rev Anticancer Ther. 2024;24.
    PubMed         Abstract available
    
    

    
    Folia Med (Plovdiv)

36. SHISHKOV DD, Shishkov DG, Todorov S, Mihaylov N, et al
    Laparoscopic vs. open surgical access radical cystectomy with subsequent orthotopic reconstruction in the treatment of invasive urothelial carcinoma of the bladder.
    Folia Med (Plovdiv). 2023;65:894-901.
    PubMed         Abstract available
    
    

    
    Gene

37. SILVA IMD, Vacario BGL, Okuyama NCM, Barcelos GRM, et al
    Polymorphisms in drug-metabolizing genes and urinary bladder cancer susceptibility and prognosis: Possible impacts and future management.
    Gene. 2024;907:148252.
    PubMed         Abstract available
    
    

    
    Heliyon

38. PAN G, Xie H, Xia Y
    Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Heliyon. 2024;10:e25573.
    PubMed         Abstract available
    
    

    
    Indian J Pathol Microbiol

39. CHENNIAPPAN A, Stephen NS, Srinivas BH, Sreenivasan SK, et al
    Plasmacytoid urothelial carcinoma with duodenal metastasis-A rare tumor with unusual site of metastasis with grim outcome.
    Indian J Pathol Microbiol. 2024;67:175-177.
    PubMed         Abstract available
    
    
40. GUPTA RK, Wasnik P, Sharma AR
    Papillary urothelial neoplasm of low malignant potential with osseous metaplasia in a 19-year-old chronic smoker: A case report with review of literature.
    Indian J Pathol Microbiol. 2024;67:159-161.
    PubMed         Abstract available
    
    

    
    Int J Hyperthermia

41. XU Y, Sun G, Yang T, Li H, et al
    Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model.
    Int J Hyperthermia. 2024;41:2316085.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

42. LI AH, Park SY, Li P, Zhou C, et al
    Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells.
    Int J Mol Sci. 2024;25:1783.
    PubMed         Abstract available
    
    
43. KUSTRIMOVIC N, Bilato G, Mortara L, Baci D, et al
    The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.
    Int J Mol Sci. 2024;25:1732.
    PubMed         Abstract available
    
    
44. GILL E, Perks CM
    Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.
    Int J Mol Sci. 2024;25:1557.
    PubMed         Abstract available
    
    

    
    Int J Surg

45. WEI Z, Xv Y, Liu H, Li Y, et al
    A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study.
    Int J Surg. 2024 Feb 13. doi: 10.1097/JS9.0000000000001194.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

46. MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
    Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study.
    Int Urol Nephrol. 2024;56:965-972.
    PubMed         Abstract available
    
    
47. ZHAI H, Wang Y, Chen Z, Wang Z, et al
    Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
    Int Urol Nephrol. 2024;56:941-955.
    PubMed         Abstract available
    
    
48. KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
    Strong apoptotic response of testis tumor cells following cisplatin treatment.
    Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
    PubMed         Abstract available
    
    

    
    Integr Cancer Ther

49. MAIMON Y, Amiel G, Cohen Z, Hoffman A, et al
    Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case Series Study.
    Integr Cancer Ther. 2024;23:15347354241233233.
    PubMed         Abstract available
    
    

    
    J Clin Med

50. FAN LW, Li YR, Wu CM, Chuang KT, et al
    Inpatient Outcomes of Patients Undergoing Robot-Assisted versus Laparoscopic Radical Cystectomy for Bladder Cancer: A National Inpatient Sample Database Study.
    J Clin Med. 2024;13:772.
    PubMed         Abstract available
    
    

    
    J Coll Physicians Surg Pak

51. CETIN T, Bolat D, Cesur G, Erdemoglu O, et al
    Comparison of Monopolar Versus Bipolar Repeat Transurethral Resection of Bladder Tumours.
    J Coll Physicians Surg Pak. 2024;34:230-234.
    PubMed         Abstract available
    
    

    
    J Urol

52. BOCHNER BH, Kamat AM, Bivalacqua TJ
    Open vs Robotic Cystectomy: Case Closed?
    J Urol. 2024;211:473-475.
    PubMed        
    
    

    
    JAMA Oncol

53. NECCHI A, Faltas BM, Slovin SF, Meeks JJ, et al
    Immunotherapy in the Treatment of Localized Genitourinary Cancers.
    JAMA Oncol. 2023;9:1447-1454.
    PubMed         Abstract available
    
    
54. KATIMS AB, Tallman J, Vertosick E, Porwal S, et al
    Response to 2 Induction Courses of Bacillus Calmette-Guerin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.
    JAMA Oncol. 2024 Feb 15. doi: 10.1001/jamaoncol.2023.6804.
    PubMed         Abstract available
    
    

    
    Lakartidningen

55. LIEDBERG F, Hagberg O, Aljabery F, Falini V, et al
    [Radical cystectomy for bladder cancer is a complex procedure].
    Lakartidningen. 2024;121:23132.
    PubMed         Abstract available
    
    

    
    Med

56. ZHU X, Koshkin VS
    Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Med. 2024;5:106-108.
    PubMed         Abstract available
    
    
57. MATHEW THOMAS V, Grivas P, Agarwal N
    Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
    Med. 2024;5:109-111.
    PubMed         Abstract available
    
    

    
    Mol Cancer

58. XIE T, Peng S, Liu S, Zheng M, et al
    Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
    Mol Cancer. 2024;23:30.
    PubMed         Abstract available
    
    

    
    Mol Oncol

59. RAC G, Patel HD, James C, Desai S, et al
    Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy.
    Mol Oncol. 2024;18:291-304.
    PubMed         Abstract available
    
    

    
    Nat Commun

60. AMARA CS, Kami Reddy KR, Yuntao Y, Chan YS, et al
    The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
    Nat Commun. 2024;15:1373.
    PubMed         Abstract available
    
    
61. RIJNDERS M, Nakauma-Gonzalez JA, Robbrecht DGJ, Gil-Jimenez A, et al
    Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
    Nat Commun. 2024;15:1349.
    PubMed         Abstract available
    
    

    
    Neuropathol Appl Neurobiol

62. TAUZIEDE-ESPARIAT A, Masliah-Planchon J, Tran S, Filser M, et al
    Brain metastasis of a urothelial neuroendocrine carcinoma: A double pitfall for neuropathologists and DNA-methylation profiling.
    Neuropathol Appl Neurobiol. 2024;50:e12951.
    PubMed        
    
    

    
    Pathol Res Pract

63. NGUYEN NJ, Sherman C, van der Kwast TH, Downes MR, et al
    Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Pathol Res Pract. 2024;254:155105.
    PubMed         Abstract available
    
    

    
    Pharm Biol

64. LUO S, Huang X, Li S, Chen Y, et al
    Homogeneous Polyporus polysaccharide exerts anti-bladder cancer effects via autophagy induction.
    Pharm Biol. 2024;62:214-221.
    PubMed         Abstract available
    
    

    
    Radiat Oncol

65. ALI M, Koo K, Chang D, Chan P, et al
    Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
    Radiat Oncol. 2024;19:23.
    PubMed         Abstract available
    
    

    
    Sci Rep

66. LEE CU, Lee JH, Lee HW, Chung JH, et al
    Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma.
    Sci Rep. 2024;14:3497.
    PubMed         Abstract available
    
    

    
    Transl Res

67. LI M, Yan X, Liu H, Miao W, et al
    Novel MSH2 and TSC2 variants in a Chinese family with Lynch syndrome and their synergistic impact in urothelial carcinoma.
    Transl Res. 2024;265:26-35.
    PubMed         Abstract available
    
    

    
    Urol Oncol

68. YILMAZ H, Teke K, Suer E, Izol V, et al
    Does neo-adjuvant chemotherapy improve the negative effect of lymphovascular invasion in survival after radical cystectomy?
    Urol Oncol. 2024;42:30.
    PubMed         Abstract available
    
    
69. LUO S, Wu Y, Yang R, Huang G, et al
    Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC.
    Urol Oncol. 2024;42:30.
    PubMed         Abstract available
    
    
70. GWAK CH, Suh J, Lim B, Song C, et al
    Preoperative C-reactive protein to albumin ratio as a novel prognostic biomarker for the oncological outcomes of radical nephroureterectomy.
    Urol Oncol. 2024;42:30.
    PubMed         Abstract available
    
    
71. KARAHAN I, Bilgin B
    Is my patient with urothelial cancer (in)eligible for platinum?
    Urol Oncol. 2024;42:27.
    PubMed        
    
    

    
    Urologie

72. VOS N, Minner J, Bohm J
    [Paraganglioma of the urinary bladder-a rare, but relevant differential diagnosis].
    Urologie. 2024;63:168-170.
    PubMed         Abstract available
    
    

    
    World J Urol

73. ORTNER G, Guven S, Somani BK, Nicklas A, et al
    Experts' recommendations in laser use for the treatment of bladder cancer: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training and Research in Urological Surgery and Technology (TRUST)-Group.
    World J Urol. 2024;42:79.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.